Artgen Biotech PJSC (MIC:ABIO) Short-Term Debt: ₽85 Mil (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIC:ABIO Artgen Biotech PJSC MIC:ABIO
17 GF Score
Price ₽45.46
View Full Analysis

What is Artgen Biotech PJSC Short-Term Debt?

Artgen Biotech PJSC MIC:ABIO +2.02% 17 Short-Term Debt is ₽85 Mil as of Jun. 2023. GuruFocus rates MIC:ABIO with a GF Score™ of 17/100.

Artgen Biotech PJSC's Short-Term Debt for the quarter that ended in Jun. 2023 was ₽85 Mil.

Artgen Biotech PJSC's quarterly Short-Term Debt increased from Jun. 2022 (₽0 Mil) to Dec. 2022 (₽107 Mil) but then declined from Dec. 2022 (₽107 Mil) to Jun. 2023 (₽85 Mil).

Artgen Biotech PJSC's annual Short-Term Debt declined from Dec. 2020 (₽178 Mil) to Dec. 2021 (₽0 Mil) but then increased from Dec. 2021 (₽0 Mil) to Dec. 2022 (₽107 Mil).

Artgen Biotech PJSC Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Artgen Biotech PJSC Short-Term Debt Related Terms

Artgen Biotech PJSC Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Artgen Biotech PJSC's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Artgen Biotech PJSC Short-Term Debt Chart

Artgen Biotech PJSC Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 50.65 138.38 177.95 0.20 107.17

Artgen Biotech PJSC Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 147.91 0.20 0.00 107.17 85.44
MIC:ABIO
17GF Score
Artgen Biotech PJSC MIC:ABIO
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of ₽85 Mil mean?
Artgen Biotech PJSC (MIC:ABIO) has a Short-Term Debt of ₽85 Mil as of Jun. 2023.
Is Artgen Biotech PJSC's Short-Term Debt too high?
Artgen Biotech PJSC's current Short-Term Debt is ₽85 Mil. Overall, Artgen Biotech PJSC has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Artgen Biotech PJSC's Short-Term Debt compare to VRTX and REGN?
Artgen Biotech PJSC's Short-Term Debt of ₽85 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Artgen Biotech PJSC's current Short-Term Debt is ₽85 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artgen Biotech PJSC stock overvalued right now?
Artgen Biotech PJSC (MIC:ABIO) has a current Short-Term Debt of ₽85 Mil. The current Short-Term Debt is ₽85 Mil. Artgen Biotech PJSC's overall GF Score™ is 17/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Artgen Biotech PJSC (MIC:ABIO), the current Short-Term Debt is ₽85 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Artgen Biotech PJSC Business Description

Address Prospect of the 60th Anniversary, Moscow, RUS, 117036
Artgen Biotech PJSC is a biotechnology company. It is engaged in the drug discovery, research and development and marketing of proprietary products and services in the field of regenerative medicine, bio-insurance, medical genetics, including reproductive genetics, gene therapy, and biopharmaceutics. The company has developed Neovasculgen, which is a gene therapy drug for the treatment of Peripheral Arterial Disease, including Critical Limb Ischemia and also develops SPRS therapy which entails the use of autologous dermal fibroblasts to repair skin damage due to aging and other structural changes.
17GF Score

Get the complete analysis for MIC:ABIO

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₽45.46
Price